After more than a year of deliberation, the U.S. Senate and the U.S House of Representatives passed the Inflation Reduction Act of 2022, and it was signed into law by the President on August 16, 2022. What does this mean for healthcare? To Medicare? To drug pricing? In this webinar, our Milliman consultants unpack what is in the bill and discuss its potential implications on the healthcare market.
Related Insight
- Weathering the reform storm: The Inflation Reduction Act’s changes to Medicare and other healthcare markets
- Is Build Back Better Back? Overview of New Schumer Drug Pricing Reform
- The Build Back Better (BBB) Act: Stakeholder implications of proposed Medicare Part D redesign
- The Build Back Better (BBB) Act: Stakeholder implications of proposed drug pricing changes